Shares of Insmed Incorporated (NASDAQ:INSM – Get Free Report) have earned an average recommendation of “Buy” from the sixteen ratings firms that are presently covering the firm, MarketBeat Ratings reports. Sixteen analysts have rated the stock with a buy rating. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $79.19.
A number of analysts have recently weighed in on the company. Mizuho increased their price objective on Insmed from $36.00 to $82.00 and gave the company a “buy” rating in a research note on Friday, June 7th. Morgan Stanley boosted their price objective on shares of Insmed from $60.00 to $85.00 and gave the company an “overweight” rating in a research report on Friday, July 12th. Barclays increased their target price on shares of Insmed from $40.00 to $63.00 and gave the stock an “overweight” rating in a report on Wednesday, May 29th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Insmed in a research report on Thursday, June 20th. Finally, HC Wainwright reiterated a “buy” rating and issued a $90.00 price objective on shares of Insmed in a report on Thursday, August 29th.
Get Our Latest Analysis on Insmed
Institutional Trading of Insmed
Insmed Price Performance
INSM stock opened at $71.04 on Wednesday. The company has a debt-to-equity ratio of 25.05, a quick ratio of 2.53 and a current ratio of 2.71. The firm has a market cap of $10.56 billion, a P/E ratio of -13.66 and a beta of 1.16. The firm’s fifty day moving average is $73.77 and its 200 day moving average is $48.45. Insmed has a 52 week low of $21.92 and a 52 week high of $80.53.
Insmed (NASDAQ:INSM – Get Free Report) last released its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($1.94) EPS for the quarter, missing the consensus estimate of ($1.22) by ($0.72). The firm had revenue of $90.34 million during the quarter, compared to analysts’ expectations of $87.95 million. The company’s revenue for the quarter was up 17.0% on a year-over-year basis. During the same quarter in the prior year, the company posted ($1.78) EPS. Research analysts predict that Insmed will post -5.42 earnings per share for the current year.
Insmed Company Profile
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.
Featured Articles
- Five stocks we like better than Insmed
- Election Stocks: How Elections Affect the Stock Market
- Does GTA VI Make Take-Two Interactive Stock an Irresistible Buy?
- About the Markup Calculator
- Why HPE’s Dip Is a Prime Opportunity for Blue-Chip AI Investors
- Investing In Automotive Stocks
- Why Analysts See Big Upside for Occidental Petroleum Despite Lows
Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.